If confirmed by the Senate, Califf would also play a key role in charting the government's wider pharmaceutical and
tobacco policy ambitions — as well as managing growing scrutiny of the FDA's drug approval process.
"He is somebody who is deeply interested in clinical evidence and basically built his career around it," Blum said. "Rob understands the appropriate proper interplay between the private sector and the public sector, both in terms of science, industry and regulatory matters. He's certainly not a shill for any one stakeholder. He demonstrated that when he was already at FDA."
